Life Sciences IPO Market Remains Consistently Strong in 2018, With Q3 No Exception
Life sciences with biotech companies paving the way represent a significant portion of IPOs in 2018. The sector continued to attract investor dollars in Q3, and is No. 1 in the deal-count category with 20, representing $1.51 billion in capital invested.
In this PDF, we quantify Q3 IPO activity in life sciences, and compare YTD with last year. There is no reason to believe that life sciences’ momentum has peaked, because IPOs in the industry continue to offer significant returns.